Topics

MASLD/MASH: Pathogenesis And Therapeutic Advances

Metabolic Diseases Chronic Inflammation Oxidative Stress Mitochondrial Dysfunction

MASLD describes steatotic liver disease with cardiometabolic risk, and MASH describes the inflammatory, hepatocyte-injury form that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. The terminology replaced NAFLD/NASH to align diagnosis with metabolic dysfunction rather than alcohol exclusion, making MASLD/MASH central to hepatology, endocrinology, obesity medicine, and cardiovascular risk management[1][2].

Pathogenesis begins with insulin resistance, adipose dysfunction, hepatic lipid overload, lipotoxicity, mitochondrial stress, oxidative stress, gut-liver signaling, inflammatory cytokines, and stellate-cell activation. Fibrosis stage is the strongest clinical anchor because progressive matrix deposition links MASH biology to liver-related outcomes, while obesity and type 2 diabetes accelerate progression and complicate management[2][3].

Therapeutic development now targets metabolic injury, steatohepatitis, and fibrosis. Lifestyle intervention, weight loss, exercise, and cardiometabolic risk control remain first-line therapy. Resmetirom, a liver-directed thyroid hormone receptor agonist, improved MASH resolution and fibrosis endpoints in phase 3 disease with fibrosis. Semaglutide increased NASH resolution in a phase 2 trial, and tirzepatide improved MASH resolution without worsening fibrosis in phase 2 MASH with fibrosis[2][4][5][6].

The field is moving toward combination and precision therapy because single agents do not fully address heterogeneous metabolic, inflammatory, fibrotic, and genetic drivers. Future priorities include noninvasive fibrosis biomarkers, patient stratification by diabetes, obesity, and genetic risk, long-term outcomes beyond histology, cirrhosis-stage therapies, and combinations that pair weight-loss biology with liver-directed antifibrotic or lipid-metabolic mechanisms[2][4][6].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-15371 Forskolin
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin is also an inducer of intracellular cAMP formation. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy.
Organoid   Adenylate Cyclase   FXR   Autophagy   PKC  
Glucose Metabolism   Non-Small Cell Lung Cancer   Hypertension  
233
HY-16578 GW9662
GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
PPAR  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
228
HY-17386 Rosiglitazone
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM), with blood-brain barrier permeability. Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.
PPAR   TRP Channel   Autophagy   Ferroptosis   Apoptosis  
Digestive System Disease   Prostate Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Non-Small Cell Lung Cancer   SARS-CoV-2 Infection   Type 2 Diabetes   Obesity  
197
HY-14649 Retinoic acid
Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
Organoid   RAR/RXR   PPAR   Endogenous Metabolite   Autophagy  
Cancer   Digestive System Disease   Depression   Digestive System Inflammation   Obesity  
150
HY-12222 Obeticholic acid
Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy.
FXR   Autophagy  
Digestive System Disease   Digestive System Inflammation   Glucose Metabolism  
87
HY-15372 GW6471
GW6471 is a selective peroxisome proliferator-activated receptor α (PPARα) antagonist. GW6471 reduces cancer stem cell viability, proliferation, and spheroid formation. GW6471 induces apoptosis and causes metabolic impairment including energy imbalance. GW6471 can be used for the research of paragangliomas and triple-negative breast cancer.
PPAR   Apoptosis  
Triple-Negative Breast Cancer  
85
HY-L060 Cytoskeleton Compound Library
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases. MCE designs a unique collection of 2,313 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Signaling Pathway Targeting Libraries

84
HY-L185 Anti-Fibrosis Compound Library
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Disease Focused Libraries

83
HY-L199 Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 5,024 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
83
HY-13443 Exendin-4
Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease.
GLP Receptor   Apoptosis  
Blood or Cardio-cerebrovascular Disease   Type 2 Diabetes  
72
HY-50108 GW 4064
GW 4064 is a potent FXR agonist with an EC50 of 65 nM.
FXR   Autophagy  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
57
HY-13956 Pioglitazone
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research.
PPAR   Ferroptosis  
Prostate Cancer   Pancreatic Cancer   Viral Infection   Coronavirus Infection   Depression   Digestive System Inflammation   Glucose Metabolism   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Obesity  
53
HY-114118C Semaglutide sodium
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-10626 T0901317
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
LXR   FXR   ROR   Apoptosis  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-A0070 Liothyronine sodium
Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
Thyroid Hormone Receptor   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
46
HY-P0264 Exendin(9-39) amide
Exendin (9-39) amide (Avexitide) is a competitive GLP-1R antagonist. Exendin (9-39) amide blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide can be used in research on type 2 diabetes and type 1 diabetes.
GLP Receptor  
Type 1 Diabetes   Type 2 Diabetes  
46
HY-A0070A Liothyronine
Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with Kis of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR.
Thyroid Hormone Receptor   Endogenous Metabolite  
Metabolic or Endocrine Disease  
46
HY-P0014 Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease   Type 1 Diabetes   Psoriasis   Chronic Obstructive Pulmonary Disease   Type 2 Diabetes   Obesity  
43
HY-15027 5-Aminosalicylic Acid
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
PPAR   PAK   NF-κB   Endogenous Metabolite  
Digestive System Disease   Colitis  
43
HY-16995 Pirinixic acid
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
PPAR  
Liver Cancer   Digestive System Inflammation   Obesity  
38
HY-50935 Troglitazone
Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
PPAR   Autophagy   Apoptosis   Ferroptosis  
Pancreatic Cancer   Depression   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Obesity  
36
HY-17356 Fenofibrate
Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
PPAR   Cytochrome P450   Autophagy  
Digestive System Disease   Breast Cancer   Viral Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism  
36
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-13771 Ursodeoxycholic acid
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
G protein-coupled Bile Acid Receptor 1   FXR   Angiotensin-converting Enzyme (ACE)   Endogenous Metabolite  
Cancer   SARS-CoV-2 Infection  
32
HY-13749 Sitagliptin
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
Dipeptidyl Peptidase   ERK   PKA   GLP Receptor  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity  
31
HY-W087947 EDTA dihydrate tripotassium
EDTA dihydrate tripotassium (Ethylenediaminetetraacetic acid dihydrate tripotassium) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA dihydrate tripotassium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA dihydrate tripotassium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA dihydrate tripotassium can alleviate the liver fibrosis. EDTA dihydrate tripotassium can be used for coronary artery disease and neural system disease research.
Bacterial   SOD  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-W105700 Ethylenediaminetetraacetic acid sodium hydrate
Ethylenediaminetetraacetic acid (EDTA) sodium hydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid sodium hydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid sodium hydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid sodium hydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid sodium hydrate can be used for coronary artery disease and neural system disease research.
Biochemical Assay Reagents   Bacterial   SOD  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-W127774 EDTA hydrate sodium
EDTA (Ethylenediaminetetraacetic acid) hydrate sodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA hydrate sodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA hydrate sodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA hydrate sodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
Biochemical Assay Reagents   SOD   Bacterial  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-Y0682A Ethylenediaminetetraacetic acid disodium dihydrate
Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research.
Environmental Pollutants   SOD   Bacterial   Biochemical Assay Reagents  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-76847 Chenodeoxycholic Acid
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
FXR   Endogenous Metabolite   Autophagy  
Metabolic or Endocrine Disease   Colorectal Cancer   Digestive System Inflammation   SARS-CoV-2 Infection  
26
HY-12216 Resmetirom
Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease  
25
HY-107738 Guggulsterone
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC50s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively.
Apoptosis   JNK   Akt   Caspase   FXR   Autophagy  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis  
22
HY-B0172 Lithocholic acid
Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist.
Autophagy   Endogenous Metabolite   Apoptosis   FXR  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Digestive System Inflammation   Obesity  
21
HY-18341 L-Thyroxine
L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
Thyroid Hormone Receptor   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
15
HY-P0059 Teriparatide
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research.
PTHR   Thyroid Hormone Receptor  
Cancer  
12
HY-P0054B GLP-1(7-36), amide TFA
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
GCGR  
Metabolic or Endocrine Disease  
11
HY-P0054A GLP-1(7-36), amide
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.
GCGR  
Metabolic or Endocrine Disease  
11
HY-P0054 GLP-1(7-36), amide acetate
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
GCGR  
Metabolic or Endocrine Disease  
11
HY-109083 Cilofexor
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.
FXR   Autophagy  
Digestive System Disease   Digestive System Inflammation  
11
HY-P0055 GLP-1(7-37)
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
GLP Receptor  
Metabolic or Endocrine Disease  
10
HY-N0010 Geniposidic acid
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis.
FXR   Sirtuin   TNF Receptor   Interleukin Related  
Metabolic or Endocrine Disease  
7
HY-14823 Sobetirome
Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
7
HY-141513 NH-3
NH-3 is an orally active, reversible thyroid hormone receptor (THR) antagonist with an IC50 of 55 nM. NH-3, a derivative of the selective thyromi-metic GC-1, inhibits binding of thyroid hormones to their receptor and that inhibits cofactor recruitment. NH-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Thyroid Hormone Receptor  
Neurological, Eye or Ear Disease  
5
HY-B0208 Methimazole
Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Glioblastoma   Graves’ Disease  
4
HY-N1423 Glycocholic acid
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
P-glycoprotein   Endogenous Metabolite   FXR   LPL Receptor   G protein-coupled Bile Acid Receptor 1   Apoptosis   MDM-2/p53   Bcl-2 Family   Bacterial   Caspase  
Metabolic or Endocrine Disease   Lung Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
4
HY-44134 Dimethyl 2-oxoglutarate
Dimethyl 2-oxoglutarate (Dimethyl α-ketoglutarate) is a cell-permeable derivative of 2-oxoglutarate and tricarboxylic acid cycle metabolite with antioxidant properties. Dimethyl 2-oxoglutarate inhibits Autophagy. Dimethyl 2-oxoglutarate prevents mitochondrial damage and reduces ROS production. Dimethyl 2-oxoglutarate alleviates Carbon tetrachloride (HY-Y0298)-induced liver fibrosis. Dimethyl-2-oxoglutaric acid can be used in the research of diseases such as Alzheimer's disease, diabetes, and cardiomyopathy.
Endogenous Metabolite   Drug Derivative   Autophagy   Mitochondrial Metabolism   Reactive Oxygen Species (ROS)  
Glucose Metabolism   Alzheimer's Disease   Cardiomyopathy   Hepatic Fibrosis  
4
HY-N2181 Acetylshikonin
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD).
Cytochrome P450   Apoptosis   Bacterial   Autophagy  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Bacterial Infection   Digestive System Inflammation   Glucose Metabolism  
3
HY-B0346 Propylthiouracil
Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research.
Environmental Pollutants   Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
3
HY-116374 Glycolithocholic acid
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Endogenous Metabolite  
Digestive System Disease   Digestive System Inflammation  
3
HY-P3506 Retatrutide
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
GCGR   GLP Receptor  
Obesity  
3
HY-N8599 Cichoriin
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC50 values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y14R (IC50 = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2.
Amylases   Glycosidase   Lipase   Dipeptidyl Peptidase   p38 MAPK   PPAR   P2Y Receptor   NOD-like Receptor (NLR)   SARS-CoV   Pyroptosis   GLUT   Angiotensin-converting Enzyme (ACE)   NF-κB  
Digestive System Disease   Viral Infection   Digestive System Inflammation   Obesity  
2
HY-N0546 Ligustroflavone
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
CaSR   RIP kinase   Mixed Lineage Kinase   TGF-beta/Smad  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis  
2
HY-P1136B TAT-Gap19
TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.
Gap Junction Protein  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
2
HY-P1136C TAT-Gap19 TFA
TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice.
Gap Junction Protein  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
2
HY-N0912 Rehmannioside D
Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis.
Sirtuin   Apoptosis   MDM-2/p53   Reactive Oxygen Species (ROS)   Bcl-2 Family   Caspase  
Inflammation or Immune System Disease   Hepatic Fibrosis  
2
HY-P99930 Efruxifermin
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.

Species: Human

FGFR  
Digestive System Disease   Digestive System Inflammation  
2
HY-P700468 GLP1R Protein, Human (HEK293, N-His, C-Myc)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

2
HY-P70239 GLP-1/GCG Protein, Human (HEK293, His)
GLP-1 and GCG are two proteins derived from the same precursor protein, which is encoded by the GCG-glucagon gene. The GCG protein is a counterregulatory hormone to insulin, playing a crucial role in glucose metabolism by increasing gluconeogenesis and reducing glycolysis to regulate blood glucose levels. GLP-1 protein, secreted by intestinal endocrine cells, promotes insulin secretion, regulates gastrointestinal motility, and inhibits the secretion of GCG protein. GLP-1/GCG protein, Human (HEK293, His), is a recombinant GLP-1/GCG protein expressed by HEK293 cells, with a His tag at the C-terminus, and is composed of 160 amino acids (R21-K180).

Species: Human; Source: HEK293

Cytokines and Growth Factors Peptide Hormone & Neuropeptides GLP-1

2
HY-P81160 GLP-1R Antibody
GLP-1R Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GLP-1R.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

2
HY-P1145 Glucagon-like peptide 1 (1-37), human
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
GCGR  
Metabolic or Endocrine Disease  
1
HY-N0630 Shanzhiside methyl ester
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.
GCGR  
Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
1
HY-114367 Delphinidin 3-rutinoside chloride
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes.
Endothelin Receptor   NO Synthase   Myosin   GLP Receptor  
Muscle Disease   Type 2 Diabetes  
1
HY-N1548 Prunasin
Prunasin is an orally active cyanogenic glucoside and the main metabolite of Amygdalin (HY-N0190). Prunasin can specifically inhibit rat DNA polymerase β (IC50: 98 μM). Prunasin has anti-inflammatory and anti-fibrotic activities. Prunasin can be used in the research of diseases such as liver fibrosis.
DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-P3463 Beinaglutide
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
GCGR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-N0732 Jolkinolide B
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma   Fatty Liver Disease  
1
HY-W011121 2-Oleoylglycerol
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
GPR119   NF-κB   TGF-beta/Smad   GLP Receptor  
Metabolic or Endocrine Disease  
1
HY-P72206 GLP1R Protein, Mouse (His-SUMO)
GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R Protein, Mouse (His-SUMO) is the recombinant mouse-derived GLP1R protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Species: Mouse; Source: E. coli

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

1
HY-P11274 Zenagamtide
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   GCGR   Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W777365 Ethylenediaminetetraacetic acid-13C4
Ethylenediaminetetraacetic acid-13C4 (EDTA-13C4) is the 13C-labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
Isotope-Labeled Compounds   Biochemical Assay Reagents   SOD   Bacterial  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P5345 KLA peptide
KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.
Apoptosis   Antibiotic   Caspase   Mitochondrial Metabolism  
Infection   Cerebrovascular Disease   Hepatic Fibrosis  
/
HY-P3389 Vurolenatide
Vurolenatide is a long-lasting GLP-1 analogue. Vurolenatide can be studied in research on short bowel syndrome.
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P992407 MEDI-4166
MEDI-4166 is an antibody-peptide gene fusion molecule of a PCSK9 antibody and a GLP-1 analog. MEDI-4166 is applicable to research related to type 2 diabetes.

Species: Human

PCSK9   GLP Receptor  
Autoimmune Disease  
/
HY-W750488 Glycolithocholic acid-d5
Glycolithocholic acid-d5 (Lithocholylglycine-d5) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-181896S PPARγ agonist-23
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis.
PPAR  
Digestive System Disease   Digestive System Inflammation  
/
HY-N10640 Alismanol M
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC50 value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis.
FXR  
Inflammation or Immune System Disease  
/
HY-N16066 Candidusin A
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a KD of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research.

Source: Aspergillus candidus

AMPK   Apoptosis   NF-κB   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-N21706 Hypercohin K
Hypercohin K is a polycyclic polyprenylated acylphloroglucinol isolated from Hypericum henryi, containing a rare spiro-fused cyclopropane ring in its structure. Hypercohin K exhibits anti-inflammatory, antitumor, and AChE-enhancing activities. Hypercohin K reduces intracellular lipid accumulation by regulating lipid metabolism genes, and can inhibit NO production to exert anti-inflammatory effects. Hypercohin K can be used in research on non-alcoholic steatohepatitis and tumors.
Endogenous Metabolite   NO Synthase   Cholinesterase (ChE)  
Cancer   Digestive System Disease   Digestive System Inflammation  
/
HY-P11042 TE-8105
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-127166R Colchiceine (Standard)
Colchiceine (Standard) is the analytical standard of Colchiceine. This product is intended for research and analytical applications. Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis.
Microtubule/Tubulin   Reference Standards  
Inflammation or Immune System Disease  
/
HY-P11826 T2 peptide-1
T2 peptide-1 is a linear peptide derived from Lumican degradation. T2 peptide-1 exhibits activity against endometrial adhesion progression and ability to inhibit the Lumican−Collagen I interaction. T2 peptide-1 can be used for the research of liver fibrosis.
Collagen  
Hepatic Fibrosis  
/
HY-Y0682S2 Ethylenediaminetetraacetic acid-d4
Ethylenediaminetetraacetic acid-d4 (EDTA-d4) is the deuterium labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
Isotope-Labeled Compounds   SOD   Biochemical Assay Reagents   Bacterial   Environmental Pollutants  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-13749S2 Sitagliptin-d4
Sitagliptin-d4 (MK-0431-d4) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
Isotope-Labeled Compounds   ERK   PKA   Dipeptidyl Peptidase   GLP Receptor   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-B1588S Carbenoxolone-d4
Carbenoxolone-d4 is the d4 labeled Carbenoxolone (HY-B1588). Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.
Isotope-Labeled Compounds   Amyloid-β   Gap Junction Protein  
Alzheimer's Disease   Hepatic Fibrosis  
/
HY-12216S Resmetirom-13C3,15N
Resmetirom-13C3,15N (MGL-3196-13C3,15N) is the 13C- and 15N-labeled Resmetirom (HY-12216). Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis.
Isotope-Labeled Compounds   Thyroid Hormone Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-153476 GIP/GLP-1 dual receptor agonist-1
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation  
/
HY-182832 Skim Milk powder
Skim Milk powder (Dry skim milk) is an orally effective, dairy-derived non-fat milk solid powder. Skim Milk powder serves as a nutrient source in microbial culture media and can also be used for blocking procedures in WB assays. Skim Milk powder protects zebrafish sperm from oxidative stress, DNA damage, membrane disruption and morphological abnormalities during cryopreservation, and improves their survival rate. After undergoing high Maillard reaction during moist-heat storage, Skim Milk powder exhibits negative metabolic activities such as inhibiting GLP-1/GIP and promoting intestinal inflammation. Skim Milk powder can be used in studies related to intestinal inflammation, diabetes and obesity.
DNA/RNA Synthesis   GLP Receptor  
Glucose Metabolism   Inflammatory Bowel Disease   Obesity  
/
HY-B0149S3 Tranexamic acid-13C2,15N
Tranexamic acid-13C2,15N (Cyclocapron-13C2,15N) is the 13C2 and 15N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury.
Isotope-Labeled Compounds  
Inflammation or Immune System Disease  
/
HY-N16478 Echihumiline
Echihumiline is an alkaloid targeting hepatic cytochrome P450 enzymes (CYP450). Echihumiline induces DNA cross-linking and oxidative stress in hepatocytes, leading to liver necrosis and fibrosis. Echihumiline is promising for research of liver diseases.
Cytochrome P450  
Metabolic or Endocrine Disease  
/
HY-N18033 Glyceollin III
Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes.
Insulin Receptor   GLP Receptor  
Type 2 Diabetes  
/
HY-P11348 TG-MMP-Lys
TG-MMP-Lys is an MMP-sensitive crosslinking peptide. TG-MMP-Lys is promising for research of fibrotic diseases (e.g., liver fibrosis).
MMP  
Cancer  
/
HY-P11549 pPB peptide
pPB peptide is a cyclic peptide targeting platelet-derived growth factor receptor β (PDGFRβ). Derived from natural platelet-derived growth factor (PDGF), pPB peptide contains arginine and isoleucine as key receptor-binding residues. pPB peptide specifically binds to PDGFRβ, which is highly expressed on the surface of activated hepatic stellate cells (HSC). pPB peptide can be used in studies related to liver fibrosis, liver cirrhosis, and tumor-specific drug delivery.
PDGFR  
Cancer   Lung Fibrosis  
/
HY-172836S GLP-1 receptor agonist 17-d3
GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
GCGR  
Blood or Cardio-cerebrovascular Disease  
/
HY-W701772 2-Oleoylglycerol-d5
2-Oleoylglycerol-d5 (2-OG-d5) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
Isotope-Labeled Compounds   NF-κB   TGF-beta/Smad   GPR119   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P5345A KLA peptide acetate
KLA peptide acetate is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide acetate can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA acetate, formed by the coupling of KLA peptide acetate with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide acetate can be used for the research of liver fibrosis. KLA peptide acetate can be used for the research of neonatal hypoxic-ischemic encephalopathy.
Apoptosis   Antibiotic   Caspase   Mitochondrial Metabolism  
Infection   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Hepatic Fibrosis  
/
HY-P11207 NLS-CPP
NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA).
Others  
Inflammation or Immune System Disease  
/
HY-P11208A mNLS-CPP-scramble
mNLS-CPP-scramble is a negative control peptide of mNLS-CPP-WSTF. mNLS-CPP-scramble is promising for research of chronic inflammatory diseases (e.g., MASH, osteoarthritis).
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-N21699 Uralione E
Uralione E is a naturally occurring polycyclic polyprenylated acylphloroglucinol (PPAP). Uralione E exhibits a protective effect against corticosterone (HY-B1618)-induced damage in PC12 cells. In a free fatty acid (FFA)-induced L02 cell model, Uralione E dose-dependently reduces intracellular lipid accumulation, downregulates the expression of FASN and CD36, and upregulates the expression of ACOX1 and PPARα. Uralione E can be used in studies related to neuronal cell damage, lipid metabolism, and non-alcoholic steatohepatitis.
Fatty Acid Synthase (FASN)   PPAR  
Digestive System Disease   Digestive System Inflammation  
/
HY-N0732R Jolkinolide B (Standard)
Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
Reference Standards   IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma  
/
HY-P11827 C11 peptide-1
C11 peptide-1 is an antifibrotic agent that binds directly to Collagen I. C11 peptide-1 physically disrupts Collagen I interaction with Lumican. C11 peptide-1 reduces inflammatory infiltration and inhibits the ERK1/2 and Smad2/3 signaling pathways. C11 peptide-1 can be used for the research of liver fibrosis.
Collagen   ERK   TGF-beta/Smad  
Hepatic Fibrosis  
/
HY-P6177 SGP8
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH).
Dipeptidyl Peptidase  
Inflammation or Immune System Disease  
/
HY-P11208 mNLS-CPP-WSTF
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-113806 (±)-Trolline
(±)-Trolline ((±)-Oleracein E), an isoquinoline alkaloid, exhibits antibacterial activity against respiratory bacteria and antiviral activity against influenza virus A and B. (±)-Trolline significantly induces HSC apoptosis. (±)-Trolline can be used for the research of liver fibrosis.
Bacterial   Influenza Virus   Apoptosis  
Inflammation or Immune System Disease  
/
HY-N0630R Shanzhiside methyl ester (Standard)
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.
Reference Standards   GCGR  
Neurological, Eye or Ear Disease  
/
HY-P2032 Cyclochlorotine
Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity.

Source: Penicillium islandicum

Endogenous Metabolite  
Cancer   Infection  
/
HY-N0546R Ligustroflavone (Standard)
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
Reference Standards   CaSR   RIP kinase   Mixed Lineage Kinase   TGF-beta/Smad  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-127166 Colchiceine
Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis.
Microtubule/Tubulin  
Inflammation or Immune System Disease  
/
HY-P0119S Lixisenatide (Leu-13C6,15N) TFA
Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
Isotope-Labeled Compounds   GLP Receptor   Akt   MEK   Apoptosis   Reactive Oxygen Species (ROS)   MMP  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-13749S3 Sitagliptin-d6
Sitagliptin-d6 (MK-0431-d6) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
Isotope-Labeled Compounds   PKA   Endogenous Metabolite   GLP Receptor   Dipeptidyl Peptidase   ERK  
Metabolic or Endocrine Disease  
/
HY-P0014AS Liraglutide-d8 tetraTFA
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P1624S Teduglutide-Ala(13C3,15N) sodium
Teduglutide-Ala(13C3,15N) (ALX-0600-Ala(13C3,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-15790S Elobixibat-d5
Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
Isotope-Labeled Compounds   Apical Sodium-Dependent Bile Acid Transporter  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P990989 Efmedaglutide alfa
HY-P990989 is an GLP-1 receptor-targeting Fusion Protein.
GLP Receptor  
Inflammation or Immune System Disease  
/
HY-P1624S1 Teduglutide-Leu(13C6,15N) sodium
Teduglutide-Leu(13C6,15N) (ALX-0600-Leu(13C6,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-N9610 Coenzyme Q6
Coenzyme Q6 (Ubiquinone 30) is a redox-active benzoquinone lipid and mitochondrial electron carrier. Coenzyme Q6 can be used in research on MASLD, mitochondrial diseases, pneumococcal diseases, and steroid-resistant nephrotic syndrome with FSGS.

Source: saccharomyces

Endogenous Metabolite  
Renal Disease   Streptococcus Pneumoniae Infection   Fatty Liver Disease  
/
HY-P990990 Efsubaglutide alfa
Efsubaglutide alfa is a long-acting humanised GLP-1 receptor agonist. Efsubaglutide alfa binds specifically to the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and promoting β-cell proliferation and increased β-cell mass. Efsubaglutide alfa improves glucose tolerance, increases pancreatic insulin content, and enhances β-cell secretory responses in isolated human islets. Efsubaglutide alfa reduces liver steatosis, lowers NAFLD Activity Scores, improves perisinusoidal collagen features, reduces serum ALT and AST levels, improves fasting glucose and triglyceride levels, and reduces body weight, liver weight and liver-to-body weight ratio. Efsubaglutide alfa can be used for the research of type 2 diabetes. Efsubaglutide alfa can be used for the research of metabolic dysfunction-associated steatohepatitis.

Species: Human

GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes  
/
HY-113513 5-HEPE
5-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). 5(S)-HEPE increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Source: Caenorhabditis elegan

Others  
Cancer  
/
HY-116374R Glycolithocholic acid (Standard)
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Endogenous Metabolite   Reference Standards  
Inflammation or Immune System Disease  
/
HY-P11208C mNLS-CPP-WSTF TFA
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-P11208B mNLS-CPP-scramble TFA
mNLS-CPP-scramble (TFA) is the trifluoroacetate salt of mNLS-CPP-scramble (HY-P11208A). mNLS-CPP-scramble is a negative control peptide of mNLS-CPP-WSTF. mNLS-CPP-scramble is promising for research of chronic inflammatory diseases (e.g., MASH, osteoarthritis).
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-P991099 Anti-GLP1R Antibody
Anti-GLP1R Antibody is a human antibody expressed in CHO cells, targeting GLP1R. Anti-GLP1R Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

GCGR  
Metabolic or Endocrine Disease  
/
HY-P0014S2 Liraglutide-13C6,15N TFA
Liraglutide-13C6,15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds  
/
HY-13749S1 Sitagliptin-d4 hydrochloride
Sitagliptin-d4 hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.
Dipeptidyl Peptidase   PKA   Isotope-Labeled Compounds   GLP Receptor   Endogenous Metabolite   ERK  
Metabolic or Endocrine Disease  
/
HY-153476A GIP/GLP-1 dual receptor agonist-1 sodium
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation  
/
HY-P5311 Albiglutide
Albiglutide is a long acting GLP-1 receptor agonist. Albiglutide is a recombinant fusion protein consisting of two copies of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36), modified with a glycine substituted for the naturally occurring alanine at position 8 in order to augment resistance to DPP-4. Albiglutide can be used for research of Type 2 diabetes.

Species: Human

GLP Receptor  
Type 2 Diabetes  
/
HY-13749AS Sitagliptin-d4 phosphate
Sitagliptin-d4 phosphate (MK-0431-d4) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.
PKA   Dipeptidyl Peptidase   Endogenous Metabolite   ERK   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-114118S1 Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-145632A Pemvidutide TFA
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-Y0850U3 PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization)
PVA (Polyvinyl alcohol) (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is a water-soluble, biodegradable, biocompatible and non-immunogenic polymer. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) causes no irritation to rabbit eyes, no skin sensitization in guinea pigs, promotes the proliferation of human skin keratinocytes, and reduces the loss of corneal endothelial cells. The LD50 of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) in rats and dogs is greater than 10 g/kg. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is hardly absorbed by the digestive system, causes no adverse effects upon long-term oral administration, and shows no mutagenicity or carcinogenicity. However, repeated intravenous or portal vein injection of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) may induce pathological changes such as glomerular lesions, anemia, hypertension or liver fibrosis in rats or dogs. Crosslinked nanofibers prepared by modifying PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) can be used in studies related to wound dressings and other applications.
Biochemical Assay Reagents  
/
HY-116374S Glycolithocholic acid-d4
Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P5815 GLP-1 (1-36) amide (human, rat)
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
/
HY-P99428 Aldafermin
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH).
Others  
Metabolic or Endocrine Disease  
/
HY-P10929 Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist.
Drug Intermediate  
/
HY-N7426 3-Deoxyglucosone
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.
GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Glucose Metabolism  
/
HY-N0500 Mogroside III
Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC50 value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology.
Glycosidase   Autophagy  
Prostate Cancer   Depression   Pain   Glucose Metabolism  
/
HY-P990013 Gulgafafusp alfa
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R.

Species: Human

GCGR  
Metabolic or Endocrine Disease  
/
HY-N6911A 18α-Licorice-saponin H2
18α-Glycyrrhizic acid (18α-GA; Isoglycyrrhizinic acid; 18α-Glycyrrhizic acid) is a derivative of glycyrrhizic acid with oral activity. 18α-Glycyrrhizic acid exhibits antioxidant, anti-inflammatory, hepatoprotective and cardioprotective activities. 18α-Glycyrrhizic acid protects against ethanol-induced alcoholic liver disease in rats by upregulating the expression levels of SOD, GSH, PPAR-α and CPT-1. 18α-Glycyrrhizic acid shows cytotoxicity against T lymphocytes and inhibits HIV-1 replication in these cells. 18α-Glycyrrhizic acid alleviates oxidative stress by reducing the levels of ROS, Nrf2, HO-1 and p-P65, and alleviates pyroptosis by downregulating the expression levels of NLRP3, GSDMD-N, P20 and c-IL-1β. 18α-Glycyrrhizic acid inhibits autophagy, colonic fibrosis and myocardial fibrosis, and regulates intestinal barrier integrity. 18α-Glycyrrhizic acid can be used in research related to alcoholic liver disease, HIV-1 infection, hepatotoxicity, acute liver failure, inflammatory bowel disease and myocardial fibrosis.
SOD   PPAR   Carnitine Palmitoyltransferase (CPT)   HIV   Reactive Oxygen Species (ROS)   Keap1-Nrf2   Heme Oxygenase (HO)   NOD-like Receptor (NLR)   Interleukin Related   Pyroptosis   Autophagy   NF-κB   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-128421 Tridecanedioic acid
Tridecanedioic acid (Brassylic Acid) is a long-chain fatty acid and an endogenous serum metabolite. Tridecanedioic acid is positively correlated with the intestinal genus Tuzzerella in non-alcoholic steatohepatitis (NASH) mice fed a MCD diet. Tridecanedioic acid accumulates at high levels in Brassica napus germplasm tolerant to Plutella xylostella (diamondback moth), thereby participating in plant defense. Tridecanedioic acid can be used in studies related to Plutella xylostella infestation.
Endogenous Metabolite   Insecticide  
Digestive System Disease   Plant Infection   Digestive System Inflammation  
/
HY-114118S Semaglutide-d8
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-108795 Albiglutide fragment
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies.
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-145632 Pemvidutide
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-N5020 Carabrone
Carabrone is a sesquiterpene found in the fruits of Carpesium abrotanoides and acts as a STAT3 inhibitor (Kd = 25.23 nM) with antibacterial, antitumor, and orally active properties. Carabrone covalently binds to UBE2D3 via Cys85 (Kd = 3.85 μM) and inhibits IκBα phosphorylation and NF-κB signaling. Carabrone induces ROS accumulation, loss of mitochondrial membrane potential, DNA fragmentation, and metacaspase-1-mediated apoptosis in fungi. Carabrone ameliorates autoimmune encephalomyelitis and MASH in vivo, reduces pro-inflammatory cytokines without immunotoxicity. Carabrone is used in research related to autoimmune encephalomyelitis, steatohepatitis, and fungal infections.
STAT   Fungal   NF-κB   Reactive Oxygen Species (ROS)   Apoptosis  
Cancer   Fungal Infection   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P1348 GLP-1 moiety from Dulaglutide
GLP-1 moiety from Dulaglutide ([Gly8,36,Glu22]-GLP-1 (7-37)) is a 31-amino acid fragment derived from Dulaglutide (HY-P0120). GLP-1 moiety from Dulaglutide is a DPP-4-modified GLP-1 analog carrying the [Gly8,36,Glu22] sequence mutation, which acts as a GLP-1 receptor agonist. GLP-1 moiety from Dulaglutide covalently links to the human IgG4 Fc fragment and constitutes a part of the dulaglutide recombinant fusion protein. GLP-1 moiety from Dulaglutide exhibits glucose-dependent insulinotropic activity. GLP-1 moiety from Dulaglutide can be used in research related to type 2 diabetes.
GCGR   Dipeptidyl Peptidase   GLP Receptor  
Type 2 Diabetes  
/
HY-N9536 Cinnamtannin A2
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect.
GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Glucose Metabolism  
/
HY-P99697 Leronlimab
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

Species: Human

CCR   HIV  
Cancer   Infection  
/
HY-P0014S1 Liraglutide-13C5,15N tetraTFA
Liraglutide-13C6,15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GCGR   GLP Receptor  
/
HY-114118CP Semaglutide (crude)
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P2535 GLP-1 (7-36), amide, biotin labeled
Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P990964 Efimosfermin alfa
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia.

Species: Human

FGFR  
Inflammation or Immune System Disease   Obesity   Hypertriglyceridemia  
/
HY-114118S3 Semaglutide-13C6,15N TFA
Semaglutide-13C6,15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Metabolic or Endocrine Disease  
/
HY-P991219 Anti-IL11RA Antibody (X209)
Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a KD of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003).

Species: Human

Interleukin Related   ERK   MMP  
Inflammation or Immune System Disease  
/
HY-42680 D-Tagatose
D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
Endogenous Metabolite  
Cancer   Atherosclerosis and Inflammation   Type 2 Diabetes  
/
HY-P991049 Atrosimab
Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.

Species: Human

TNF Receptor  
Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis   Fatty Liver Disease  
/
HY-W011927 4,4'-Sulfonyldiphenol
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease  
/
HY-P99143 Anti-Mouse NK1.1 Antibody (PK136)
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH).

Species: Mouse

Neurokinin Receptor   NF-κB   STAT  
Digestive System Disease   Digestive System Inflammation  
/
HY-P11274A Zenagamtide sodium
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   Insulin Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-P1141 GLP-1(9-36)amide
GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor.
GCGR  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
/
HY-P4146 Survodutide
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes   Obesity  
/
HY-P3375 Mazdutide
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D).
GCGR   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P70352 GLP1R Protein, Human (HEK293, Fc)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P704635 GLP1R Protein, Human (HEK293, His)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, His) is the recombinant human-derived GLP1R protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705301 GLP1R Protein, Human (Biotinylated, HEK293, His-Avi)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived GLP1R protein, expressed by HEK293, with N-Avi labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Biotinylated Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P706142 GLP1R Protein, Human (Cell-Free, His)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (Cell-Free, His) is the recombinant human-derived GLP1R protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Species: Human; Source: E. coli Cell-free

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705621 GLP1R Protein, Mouse (HEK293, His)
GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R, Mouse (HEK293, His) is the recombinant mouse-derived GLP1R protein, expressed by HEK293, with labeled tag.

Species: Mouse; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705973 GLP1R Protein, Cynomolgus (HEK293, His)

Species: Cynomolgus; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705977 GLP1R Protein, Rat (HEK293, His)

Species: Rat; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P81381 MASH1/Achaete-scute homolog 1 Antibody (YA1126)
MASH1/Achaete-scute homolog 1 Antibody (YA1126) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MASH1/Achaete-scute homolog 1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811065 GLP-1 Receptor Antibody
GLP-1 Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to GLP-1 Receptor.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811650 Tirzepatide Antibody
Tirzepatide Antibody is a Rabiit-derived and non-conjugated polyclonal antibody, targeting to Tirzepatide.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P81381A MASH1/Achaete-scute homolog 1 Antibody (YA1126)(PBS only)
MASH1/Achaete-scute homolog 1 Antibody (YA1126) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MASH1/Achaete-scute homolog 1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85132 EHMT1 Antibody (YA4824)
EHMT1 Antibody (YA4824) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to EHMT1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P88034 MASH1/Achaete-scute homolog 1 Antibody (YA7719)
MASH1/Achaete-scute homolog 1 Antibody (YA7719) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MASH1/Achaete-scute homolog 1.

Host: Rabbit

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K0610 Sirius Red Staining Kit

MCE Sirius Red Staining Kit consists of hematoxylin staining solution and Sirius Red staining solution and is mainly used to observe abnormal collagen deposition or fibrosis in various pathological tissues. Under a conventional light microscope, collagen fibers in tissues such as the heart and blood vessels appear red. Under polarized light microscopy, this method is useful for the classification and evaluation of different types of fibrotic lesions.

Cell Biology Cell Analysis Staining Kit

/

Keywords

MASLD | MASH | metabolic dysfunction-associated steatotic liver disease | steatohepatitis | liver fibrosis | resmetirom | GLP-1 | tirzepatide